Prediction models for risk of diabetic kidney disease in Chinese patients with type 2 diabetes mellitus

References

• Federation ID. IDF diabetes atlas. 10th edn. Brussels, Belgium: International Diabetes Federation; 2021.
   Google Scholar
• Hagnas M, Sundqvist H, Jokelainen J, et al. The prevalence of chronic kidney disease and screening of renal function in type 2 diabetic patients in Finnish primary healthcare. Prim Care Diabetes. 2020;14(6):639–644.
   PubMed Web of Science ®Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–266.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhang H, Luo Y, et al. The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis. Ren Fail. 2021;43(1):781–795.
   PubMed Web of Science ®Google Scholar
• He D, Zhang Y, Zhang W, et al. Effects of ACE inhibitors and angiotensin receptor blockers in normotensive patients with diabetic kidney disease. Horm Metab Res. 2020;52(5):289–297.
   PubMed Web of Science ®Google Scholar
• Du YH, Guan CJ, Li LY, et al. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis. Ann Palliat Med. 2022;11(3):1093–1101.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540–552.
   PubMed Web of Science ®Google Scholar
• Verma A, Patel AB. Finerenone: a non-steroidal mineralocorticoid receptor blocker for diabetic kidney disease. Trends Endocrinol Metab. 2021;32(5):261–263.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319–334.
   PubMed Web of Science ®Google Scholar
• Gorriz JL, Soler MJ, Navarro-Gonzalez JF, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020;9(4):1–20.
   Web of Science ®Google Scholar
• Allen A, Iqbal Z, Green-Saxena A, et al. Prediction of diabetic kidney disease with machine learning algorithms, upon the initial diagnosis of type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2022;10(1):1–7.
   Web of Science ®Google Scholar
• Kong AP, Xu G, Brown N, et al. Diabetes and its comorbidities–where east meets west. Nat Rev Endocrinol. 2013;9(9):537–547.
   PubMed Web of Science ®Google Scholar
• Nephrology EGoCSo. Chinese guidelines for diagnosis and treatment of diabetic kidney disease. Chin J Nephrol. 2021;37(3):255–304.
   Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2020;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Johnson JW. A heuristic method for estimating the relative weight of predictor variables in multiple regression. Multivariate Behav Res. 2000;35(1):1–19.
   PubMed Web of Science ®Google Scholar
• Johnson JW, LeBreton JM. History and use of relative importance indices in organizational research. Organ Res Methods. 2004;7(3):238–257.
   Web of Science ®Google Scholar
• Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric diabetic kidney disease. Clin Exp Nephrol. 2020;24(7):573–581.
   PubMed Web of Science ®Google Scholar
• Argiles A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One. 2013;8(5):e62837.
   PubMed Web of Science ®Google Scholar
• Li Y, Su X, Ye Q, et al. The predictive value of diabetic retinopathy on subsequent diabetic nephropathy in patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies. Ren Fail. 2021;43(1):231–240.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2–7.
   Web of Science ®Google Scholar
• Patel DM, Bose M, Cooper ME. Glucose and blood pressure-dependent pathways – the progression of diabetic kidney disease. Int J Mol Sci. 2020;21(6):1–32.
   Web of Science ®Google Scholar
• Jalal DI, Maahs DM, Hovind P, et al. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol. 2011;31(5):459–465.
   PubMed Web of Science ®Google Scholar
• Mauer M, Doria A. Uric acid and risk of diabetic kidney disease. J Nephrol. 2020;33(5):995–999.
   PubMed Web of Science ®Google Scholar
• Li Y, Ji X, Ni W, et al. Serum albumin and albuminuria predict the progression of chronic kidney disease in patients with newly diagnosed type 2 diabetes: a retrospective study. PeerJ. 2021;9:e11735.
   PubMed Web of Science ®Google Scholar
• Zhao WB, Alberto PSM. Serum apolipoprotein B/apolipoprotein A1 ratio is associated with the progression of diabetic kidney disease to renal replacement therapy. Int Urol Nephrol. 2020;52(10):1923–1928.
   PubMed Web of Science ®Google Scholar
• Winter L, Wong LA, Jerums G, et al. Use of readily accessible inflammatory markers to predict diabetic kidney disease. Front Endocrinol. 2018;9:225.
   PubMed Web of Science ®Google Scholar
• Deray G, Heurtier A, Grimaldi A, et al. Anemia and diabetes. Am J Nephrol. 2004;24(5):522–526.
   PubMed Web of Science ®Google Scholar
• Zhao L, Li L, Ren H, et al. Association between serum alkaline phosphatase and renal outcome in patients with type 2 diabetes mellitus. Ren Fail. 2020;42(1):818–828.
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang T, Dai H, et al. Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation. J Lipid Res. 2020;61(10):1320–1327.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Liu C, et al. C-peptide, glycaemic control, and diabetic complications in type 2 diabetes mellitus: a real-world study. Diabetes Metab Res Rev. 2022;38(4):e3514.
   PubMed Web of Science ®Google Scholar
• Grimes DA. The nomogram epidemic: resurgence of a medical relic. Ann Intern Med. 2008;149(4):273–275.
   PubMed Web of Science ®Google Scholar
• Sun L, Zou LX, Han YC, et al. Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025. BMC Nephrol. 2016;17(1):60.
   PubMedGoogle Scholar
• Han YC, Huang HM, Sun L, et al. Epidemiological study of RRT-Treated ESRD in Nanjing – a ten-year experience in nearly three million insurance covered population. PLoS One. 2016;11(2):e0149038.
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang SH, Lin HW, et al. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis. J Diabetes Investig. 2018;9(1):152–161.
   PubMed Web of Science ®Google Scholar